Loading...
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor exhibited extensive infiltration by CD8(+) cytotoxic T lymphocytes, low-to-moderate mutational burden, no PD-L1 staining by commercially availa...
Na minha lista:
| Udgivet i: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279415/ https://ncbi.nlm.nih.gov/pubmed/30524881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1460298 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|